RU2013149800A - 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения расстройств нервной системы и рака - Google Patents

8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения расстройств нервной системы и рака Download PDF

Info

Publication number
RU2013149800A
RU2013149800A RU2013149800/04A RU2013149800A RU2013149800A RU 2013149800 A RU2013149800 A RU 2013149800A RU 2013149800/04 A RU2013149800/04 A RU 2013149800/04A RU 2013149800 A RU2013149800 A RU 2013149800A RU 2013149800 A RU2013149800 A RU 2013149800A
Authority
RU
Russia
Prior art keywords
cancer
pharmaceutically acceptable
syndrome
tumor
compound according
Prior art date
Application number
RU2013149800/04A
Other languages
English (en)
Inventor
Дэвид Кэмпбелл
Серджио Г. Дюрон
Original Assignee
Афраксис Холдингз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Афраксис Холдингз, Инк. filed Critical Афраксис Холдингз, Инк.
Publication of RU2013149800A publication Critical patent/RU2013149800A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Соединение, выбранное из группы, состоящей из:и его фармацевтически приемлемые соли.2. Соединение по п.129, выбранное из группы, состоящей из:и его фармацевтически приемлемые соли.3. Фармацевтическая композиция, включающая соединение по п.1 или его фармацевтически приемлемую соль и фармацевтически приемлемый эксципиент, носитель или связующее вещество.4. Способ лечения субъекта, страдающего расстройством ЦНС или раком, включающий введение субъекту терапевтически эффективного количества соединения по п. 1 или 2 или композиции по п.3.5. Способ по п.4, в котором расстройство ЦНС представляет собой шизофрению, болезнь Альцгеймера, когнитивные нарушения легкой степени, аутизм, расстройства аутистического спектра, синдром ломкой X-хромосомы, синдром Ретта, синдром Аспергера, синдром Ангельмана, биполярное расстройство и депрессию.6. Способ по п.4, в котором раковое заболевание выбрано из рака яичников, рака молочной железы, рака толстой кишки, рака головного мозга, хронического миелоидного лейкоза, почечно-клеточной карциномы, рака желудка, лейкоза, рака легких, меланомы, рака предстательной железы, T-клеточной лимфомы, гепатоцеллюлярного рака, рака мочевого пузыря, рака почки, глиобластомы, мезотелиомы, невромы, менингиомы, нейробластомы, медуллобластомы, периферической периневральной злокачественной опухоли, эпендимомы, краниофарингиомы, астроцитомы, герминомы, глиомы, смешанной глиомы, опухоли хориоидного сплетения, олигодендроглиомы, периферийной нейроэктодермальной опухоли, примитивной нейроэктодермальной опухоли (PNET), лимфомы ЦНС, аденомы гипофиза, шванномы, рака головы и шеи и рака пищевода, рака пищевода, не

Claims (8)

1. Соединение, выбранное из группы, состоящей из:
Пример Структура 40
Figure 00000001
 41
Figure 00000002
 42
Figure 00000003
 43
Figure 00000004
 44
Figure 00000005
 45
Figure 00000006
 46
Figure 00000007
 47
Figure 00000008
 48
Figure 00000009
49
Figure 00000010
 50
Figure 00000011
 51
Figure 00000012
 52
Figure 00000013
 53
Figure 00000014
 54
Figure 00000015
 55
Figure 00000016
 56
Figure 00000017
 57
Figure 00000018
 58
Figure 00000019
 59
Figure 00000020
60
Figure 00000021
 61
Figure 00000022
 62
Figure 00000023
 63
Figure 00000024
 64
Figure 00000025
 65
Figure 00000026
 66
Figure 00000027
 67
Figure 00000028
 68
Figure 00000029
 69
Figure 00000030
 70
Figure 00000031
71
Figure 00000032
 72
Figure 00000033
 73
Figure 00000034
 74
Figure 00000035
 75
Figure 00000036
 76
Figure 00000037
 77
Figure 00000038
 78
Figure 00000039
 79
Figure 00000040
80
Figure 00000041
 81
Figure 00000042
 82
Figure 00000043
 87
Figure 00000044
 88
Figure 00000045
 89
Figure 00000046
 90
Figure 00000047
 91
Figure 00000048
92
Figure 00000049
 93
Figure 00000050
 94
Figure 00000051
 95
Figure 00000052
 96
Figure 00000053
 97
Figure 00000054
 98
Figure 00000055
 99
Figure 00000056
100
Figure 00000057
 101
Figure 00000058
 114
Figure 00000059
 115
Figure 00000060
 116
Figure 00000061
 117
Figure 00000062
 119
Figure 00000063
 120
Figure 00000064
121
Figure 00000065
 122
Figure 00000066
 123
Figure 00000067
 124
Figure 00000068
 125
Figure 00000069
 126
Figure 00000070
 127
Figure 00000071
129
Figure 00000072
 130
Figure 00000073
 131
Figure 00000074
 132
Figure 00000075
 135
Figure 00000076
 136
Figure 00000077
 137
Figure 00000078
 138
Figure 00000079
139
Figure 00000080
 140
Figure 00000081
 141
Figure 00000082
 142
Figure 00000083
 143
Figure 00000084
 144
Figure 00000085
 145
Figure 00000086
 146
Figure 00000087
147
Figure 00000088
 148
Figure 00000089
 149
Figure 00000090
 150
Figure 00000091
 151
Figure 00000092
 152
Figure 00000093
 153
Figure 00000094
154
Figure 00000095
 155
Figure 00000096
 156
Figure 00000097
 157
Figure 00000098
 158
Figure 00000099
 159
Figure 00000100
 160
Figure 00000101
 161
Figure 00000102
 162
Figure 00000103
163
Figure 00000104
 164
Figure 00000105
 165
Figure 00000106
 166
Figure 00000107
 167
Figure 00000108
 168
Figure 00000109
 169
Figure 00000110
 170
Figure 00000111
171
Figure 00000112
 172
Figure 00000113
 173
Figure 00000114
 174
Figure 00000115
 175
Figure 00000116
 176
Figure 00000117
 177
Figure 00000118
 178
Figure 00000119
 179
Figure 00000120
180
Figure 00000121
 181
Figure 00000122
 182
Figure 00000123
 183
Figure 00000124
 184
Figure 00000125
 185
Figure 00000126
 186
Figure 00000127
 187
Figure 00000128
 188
Figure 00000129
189
Figure 00000130
 190
Figure 00000131
 191
Figure 00000132
 192
Figure 00000133
 193
Figure 00000134
 194
Figure 00000135
 195
Figure 00000136
 196
Figure 00000137
197
Figure 00000138
 198
Figure 00000139
 199
Figure 00000140
 200
Figure 00000141
 201
Figure 00000142
 202
Figure 00000143
 203
Figure 00000144
 204
Figure 00000145
 205
Figure 00000146
 206
Figure 00000147
207
Figure 00000148
 208
Figure 00000149
 209
Figure 00000150
 210
Figure 00000151
 211
Figure 00000152
 212
Figure 00000153
 213
Figure 00000154
 214
Figure 00000155
 215
Figure 00000156
 216
Figure 00000157
217
Figure 00000158
 218
Figure 00000159
 219
Figure 00000160
 220
Figure 00000161
 221
Figure 00000162
 222
Figure 00000163
 223
Figure 00000164
 224
Figure 00000165
 225
Figure 00000166
 226
Figure 00000167
227
Figure 00000168
 228
Figure 00000169
 229
Figure 00000170
 230
Figure 00000171
     232
Figure 00000172
 233
Figure 00000173
 234
Figure 00000174
 235
Figure 00000175
 236
Figure 00000176
237
Figure 00000177
 238
Figure 00000178
 239
Figure 00000179
 240
Figure 00000180
 241
Figure 00000181
 244
Figure 00000182
 245
Figure 00000183
 246
Figure 00000184
 247
Figure 00000185
248
Figure 00000186
 249
Figure 00000187
 250
Figure 00000188
 251
Figure 00000189
 252
Figure 00000190
 253
Figure 00000191
 254
Figure 00000192
 255
Figure 00000193
 256
Figure 00000194
257
Figure 00000195
 258
Figure 00000196
 259
Figure 00000197
 260
Figure 00000198
 261
Figure 00000199
 262
Figure 00000200
 263
Figure 00000201
 264
Figure 00000202
265
Figure 00000203
 266
Figure 00000204
 265
Figure 00000205
 266
Figure 00000206
 267
Figure 00000207
 268
Figure 00000208
 269
Figure 00000209
 270
Figure 00000210
271
Figure 00000211
 272
Figure 00000212
 273
Figure 00000213
 274
Figure 00000214
 275
Figure 00000215
 276
Figure 00000216
 277
Figure 00000217
 278
Figure 00000218
 279
Figure 00000219
280
Figure 00000220
 281
Figure 00000221
 282
Figure 00000222
 283
Figure 00000223
 284
Figure 00000125
 285
Figure 00000224
 286
Figure 00000225
 287
Figure 00000226
 288
Figure 00000227
289
Figure 00000190
 290
Figure 00000228
 291
Figure 00000229
 292
Figure 00000230
и его фармацевтически приемлемые соли.
2. Соединение по п.129, выбранное из группы, состоящей из:
Пример Структура 40
Figure 00000001
 41
Figure 00000002
 42
Figure 00000003
 43
Figure 00000004
 44
Figure 00000005
45
Figure 00000006
 46
Figure 00000007
 47
Figure 00000008
 48
Figure 00000009
 49
Figure 00000010
 50
Figure 00000011
 51
Figure 00000012
 52
Figure 00000013
 53
Figure 00000014
 54
Figure 00000015
 55
Figure 00000016
56
Figure 00000017
 57
Figure 00000018
 58
Figure 00000019
 59
Figure 00000020
 60
Figure 00000021
 61
Figure 00000022
 62
Figure 00000023
 63
Figure 00000024
 64
Figure 00000025
 65
Figure 00000026
 66
Figure 00000027
67
Figure 00000028
 68
Figure 00000029
 69
Figure 00000030
 70
Figure 00000031
 71
Figure 00000032
 72
Figure 00000033
 73
Figure 00000034
 74
Figure 00000035
 75
Figure 00000036
 76
Figure 00000037
77
Figure 00000038
 78
Figure 00000039
 79
Figure 00000040
 80
Figure 00000041
 81
Figure 00000042
 82
Figure 00000043
 87
Figure 00000044
 88
Figure 00000045
89
Figure 00000046
 90
Figure 00000047
 91
Figure 00000048
 92
Figure 00000049
 93
Figure 00000050
 94
Figure 00000051
 95
Figure 00000052
 96
Figure 00000053
97
Figure 00000054
 98
Figure 00000055
 99
Figure 00000056
 100
Figure 00000057
 101
Figure 00000058
 114
Figure 00000059
 115
Figure 00000060
 116
Figure 00000061
117
Figure 00000062
 119
Figure 00000063
 120
Figure 00000064
 121
Figure 00000065
 122
Figure 00000066
 123
Figure 00000067
 124
Figure 00000068
125
Figure 00000069
 126
Figure 00000070
 127
Figure 00000071
 129
Figure 00000072
 130
Figure 00000073
 131
Figure 00000074
 132
Figure 00000075
и его фармацевтически приемлемые соли.
3. Фармацевтическая композиция, включающая соединение по п.1 или его фармацевтически приемлемую соль и фармацевтически приемлемый эксципиент, носитель или связующее вещество.
4. Способ лечения субъекта, страдающего расстройством ЦНС или раком, включающий введение субъекту терапевтически эффективного количества соединения по п. 1 или 2 или композиции по п.3.
5. Способ по п.4, в котором расстройство ЦНС представляет собой шизофрению, болезнь Альцгеймера, когнитивные нарушения легкой степени, аутизм, расстройства аутистического спектра, синдром ломкой X-хромосомы, синдром Ретта, синдром Аспергера, синдром Ангельмана, биполярное расстройство и депрессию.
6. Способ по п.4, в котором раковое заболевание выбрано из рака яичников, рака молочной железы, рака толстой кишки, рака головного мозга, хронического миелоидного лейкоза, почечно-клеточной карциномы, рака желудка, лейкоза, рака легких, меланомы, рака предстательной железы, T-клеточной лимфомы, гепатоцеллюлярного рака, рака мочевого пузыря, рака почки, глиобластомы, мезотелиомы, невромы, менингиомы, нейробластомы, медуллобластомы, периферической периневральной злокачественной опухоли, эпендимомы, краниофарингиомы, астроцитомы, герминомы, глиомы, смешанной глиомы, опухоли хориоидного сплетения, олигодендроглиомы, периферийной нейроэктодермальной опухоли, примитивной нейроэктодермальной опухоли (PNET), лимфомы ЦНС, аденомы гипофиза, шванномы, рака головы и шеи и рака пищевода, рака пищевода, немелкоклеточной карциномы легкого, мелкоклеточной карциномы легкого и мезотелиомы.
7. Способ по п. 4, в котором рак представляет собой опухоль, связанную с нейрофиброматозом 1 типа или 2 типа.
8. Способ по п. 7, в котором опухоль, связанная с нейрофиброматозом 1 типа или 2 типа, представляет собой нейрофиброму, оптическую глиому, периферическую периневральную злокачественную опухоль, шванному, билатеральную вестибулярную шванному, эпендимому или менингиому.
RU2013149800/04A 2011-04-08 2012-04-09 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения расстройств нервной системы и рака RU2013149800A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473683P 2011-04-08 2011-04-08
US61/473,683 2011-04-08
PCT/US2012/032803 WO2013043232A2 (en) 2011-04-08 2012-04-09 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h) -ones for the treatment of nervous system disorders and cancer

Publications (1)

Publication Number Publication Date
RU2013149800A true RU2013149800A (ru) 2015-05-20

Family

ID=47915065

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013149800/04A RU2013149800A (ru) 2011-04-08 2012-04-09 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения расстройств нервной системы и рака

Country Status (15)

Country Link
US (1) US20140163026A1 (ru)
EP (1) EP2694504A4 (ru)
JP (1) JP2014513079A (ru)
KR (1) KR20140040715A (ru)
CN (1) CN103596951A (ru)
AR (1) AR085958A1 (ru)
AU (1) AU2012313399A1 (ru)
BR (1) BR112013025798A2 (ru)
CA (1) CA2832309A1 (ru)
IL (1) IL228681A0 (ru)
MX (1) MX2013011518A (ru)
RU (1) RU2013149800A (ru)
TW (1) TW201300385A (ru)
WO (1) WO2013043232A2 (ru)
ZA (1) ZA201307296B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
MX2011004017A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de agonistas glp-1 y usos de los mismos.
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP2580214A4 (en) 2010-06-09 2013-12-04 Afraxis Holdings Inc 8- (SULFONYLARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
CA2909380A1 (en) * 2013-04-21 2014-10-30 Yeda Research And Development Co. Ltd. Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
US9861625B2 (en) * 2014-01-08 2018-01-09 Duke University Methods and compositions for treating cancer through inhibition of PI3K
CN113018300A (zh) * 2014-07-09 2021-06-25 爱普制药有限责任公司 用于治疗神经病症的方法
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
US10143684B1 (en) * 2014-09-23 2018-12-04 University Of Massachusetts Aberrant sonic hedgehog signaling in neuropsychiatric disorders
TWI511868B (zh) * 2014-10-27 2015-12-11 Nat Univ Tsing Hua A Method for Instantaneous Measurement of Local Permeability Coefficient of Injection Molding
CN104402872B (zh) * 2014-11-14 2016-08-24 广东东阳光药业有限公司 一种结晶除杂方法
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
KR102236605B1 (ko) * 2016-08-15 2021-04-05 화이자 인코포레이티드 피리도피리미딘온 cdk2/4/6 억제제
JP7023080B2 (ja) * 2016-10-31 2022-02-21 東ソー株式会社 芳香族化合物の製造方法
CN106588644B (zh) * 2016-11-16 2019-03-29 杭州师范大学 一种羧酸酯类化合物的合成方法
JP7076741B2 (ja) 2016-12-27 2022-05-30 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
WO2019015593A1 (zh) * 2017-07-19 2019-01-24 江苏奥赛康药业股份有限公司 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用
MX2020013757A (es) * 2018-09-14 2021-03-02 Abbisko Therapeutics Co Ltd Inhibidor del fgfr, metodo de preparacion y aplicacion del mismo.
US20220218703A1 (en) * 2019-02-14 2022-07-14 Bridgene Biosciences, Inc. Fgfr inhibitors for the treatment of cancer
KR20200135743A (ko) * 2019-05-22 2020-12-03 보로노이 주식회사 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
RU2711613C1 (ru) * 2019-07-29 2020-01-17 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Новое n-сульфаниламидное производное пиримидин-4(1н)-она, обладающее церебропротекторной активностью для лечения хронической травматической энцефалопатии
CN111056990B (zh) * 2019-12-16 2022-06-17 爱斯特（成都）生物制药股份有限公司 一种合成1-叔丁氧羰基-4-(4-羧基苯基)哌啶的制备方法
CN112480109B (zh) * 2020-11-16 2022-04-01 浙江大学 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc GCN2 and PERK kinase inhibitors and methods of using them
KR102532692B1 (ko) * 2021-03-15 2023-05-16 (주)피알지에스앤텍 신경섬유종증 2형 증후군 예방 또는 치료용 조성물
RU2763899C1 (ru) * 2021-03-26 2022-01-11 федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации Натриевая соль 4-{ 2-[2-(4-гидрокси-3-метоксифенил)-винил]-6-этил-4-оксо-5-фенил-4H-пиримидин-1-ил} -бензсульфамида, обладающая противоопухолевым действием
CN114853753B (zh) * 2021-04-20 2023-05-09 四川大学 吡啶并[1,2-a]嘧啶酮类似物及其在制备FGFR抑制剂中的用途
CN114952441B (zh) * 2022-06-15 2023-10-13 无锡市明鑫数控磨床有限公司 一种风电trb轴承立式磨削加工工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
CN100420687C (zh) * 2002-12-20 2008-09-24 霍夫曼-拉罗奇有限公司 作为选择性kdr和fgfr抑制剂的吡啶并[2,3-d]嘧啶衍生物
KR101538412B1 (ko) * 2005-10-07 2015-07-22 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
US8674095B2 (en) * 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
EP2453896A4 (en) * 2009-07-16 2013-01-09 Afraxis Inc PROCESS FOR TREATING SCHIZOPHRENIA
AU2010303218A1 (en) * 2009-10-09 2012-05-10 Afraxis Holdings, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders
US20130225575A1 (en) * 2010-06-16 2013-08-29 Afraxis, Inc. Methods for treating neurological conditions

Also Published As

Publication number Publication date
CN103596951A (zh) 2014-02-19
JP2014513079A (ja) 2014-05-29
WO2013043232A3 (en) 2013-06-13
AR085958A1 (es) 2013-11-06
AU2012313399A8 (en) 2013-08-01
BR112013025798A2 (pt) 2016-12-20
IL228681A0 (en) 2013-12-31
EP2694504A2 (en) 2014-02-12
AU2012313399A1 (en) 2013-05-09
EP2694504A4 (en) 2014-08-27
ZA201307296B (en) 2014-12-23
KR20140040715A (ko) 2014-04-03
CA2832309A1 (en) 2013-03-28
WO2013043232A8 (en) 2013-09-12
US20140163026A1 (en) 2014-06-12
MX2013011518A (es) 2014-06-04
WO2013043232A2 (en) 2013-03-28
TW201300385A (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
RU2013149800A (ru) 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения расстройств нервной системы и рака
RU2013148728A (ru) Комбинации соединений, ингибирующих акт, и эрлотиниба и способы их применения
RU2018135317A (ru) Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
AU2016279474B2 (en) Anticancer agent
TN2015000100A1 (en) Pde9i with imidazo pyrazinone backbone
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
PH12014501695A1 (en) Pde9 inhibitors with imidazo triazinone backbone
KR20060054412A (ko) 암 치료 및 억제용 표피 성장인자 수용체 키나제 억제제와세포독성제의 배합물 용도
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
MY152949A (en) Novel phenylimidazole derivatives as pde10a enzyme inhibitors
JP2014512354A5 (ru)
EA201290517A1 (ru) Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a
JP2019520426A5 (ru)
US9828412B2 (en) Short peptide targeting EPS8 binding with EGFR and use thereof
TN2012000271A1 (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
UA112065C2 (uk) Похідні імідазолу як інгібітори ферменту pde10a
TW201914592A (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
RU2013148817A (ru) Комбинации соединений-ингибиторов акт и мек и способы их применения
KR20200126334A (ko) 면역항암 보조제
CN105732583B (zh) 一种治疗脑胶质母细胞瘤的靶向化合物
EP1917011A1 (en) Combinations comprising dmxaa for the treatment of cancer
RU2010120810A (ru) Гидратированные кристаллические сложные эфиры камптотецина для лечения рака
RU2013149635A (ru) Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря
WO2009047216A2 (en) Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors
JP2011225538A (ja) がん免疫抑制解除剤、がん免疫治療用組成物及びがん免疫治療方法

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20150410